Gastritis drug
Pro Research Analysisby 
Searched over 200M research papers for "gastritis drug"
Gastritis Drug Treatments: Efficacy and Safety
Introduction to Gastritis and Its Treatment
Gastritis, an inflammation of the stomach lining, can be caused by various factors including Helicobacter pylori infection, NSAIDs, and lifestyle habits. Effective treatment is crucial to prevent complications such as peptic ulcers and gastric cancer. This article synthesizes recent research on various pharmacological treatments for gastritis, focusing on their efficacy and safety.
Rebamipide and Its New Formulation AD-203
Efficacy Comparison
Rebamipide, a mucoprotective drug, is commonly used to treat gastritis and peptic ulcers. A recent study compared the traditional formulation (Mucosta® 100 mg) with a new formulation (AD-203 150 mg) in patients with erosive gastritis. The study found that both formulations had similar efficacy in improving gastric erosion, with no significant difference in secondary endpoints such as redness, hemorrhage, and gastrointestinal symptoms1.
Safety Profile
Both formulations exhibited similar safety profiles, with no serious adverse drug reactions reported. The incidence of adverse events was comparable between the two groups, indicating that the new formulation is as safe as the traditional one1.
Weifuchun for Chronic Atrophic Gastritis
Effectiveness
Weifuchun, a Chinese patent drug, has shown promise in treating chronic atrophic gastritis. A meta-analysis of 15 studies involving 1,488 patients revealed that Weifuchun was more effective than Western medicine and other Chinese patent medicines in improving gastric mucosal conditions and inhibiting H. pylori2.
Safety
The safety profile of Weifuchun was comparable to that of the control group, with no significant difference in adverse events, suggesting it is a safe option for long-term use2.
Fexuprazan for Acute and Chronic Gastritis
Efficacy
Fexuprazan, a novel potassium-competitive acid blocker, was evaluated for its efficacy in treating acute and chronic gastritis. The study demonstrated that both 20 mg once daily and 10 mg twice daily doses of fexuprazan were significantly more effective than placebo in improving gastric erosion and healing rates3.
Safety
The safety profile of fexuprazan was similar to that of the placebo, with no significant difference in the incidence of adverse drug reactions, making it a safe option for gastritis treatment3.
Traditional Chinese Medicine: Jian-Wei-Qu-Tong Pills and Atractylodes macrocephala Koidz
Jian-Wei-Qu-Tong Pills
A phase II trial is underway to evaluate the efficacy and safety of Jian-Wei-Qu-Tong Pills (JWQTP) for chronic non-atrophic gastritis. Preliminary results suggest that JWQTP may offer an effective alternative to conventional treatments, with a focus on improving epigastric pain and other gastrointestinal symptoms4.
Atractylodes macrocephala Koidz
Atractylodes macrocephala Koidz (AMK) has been traditionally used to treat chronic gastritis. Network pharmacology analysis identified key pathways and active ingredients that contribute to its anti-inflammatory and mucosal protective effects, providing a scientific basis for its use in gastritis treatment6.
Combination Therapies: Rebamipide and Pantoprazole
A study on the combined use of rebamipide and pantoprazole in preventing dexamethasone-induced gastritis in rats showed that rebamipide had a superior protective effect on the gastric mucosa compared to pantoprazole. The combination therapy also demonstrated significant improvement in gastric mucosal conditions7.
Conclusion
Recent studies highlight the efficacy and safety of various pharmacological treatments for gastritis, including traditional drugs like rebamipide and novel options like fexuprazan and Weifuchun. Traditional Chinese medicines such as Jian-Wei-Qu-Tong Pills and Atractylodes macrocephala Koidz also show promise. Combination therapies may offer enhanced protective effects. Further research and high-quality clinical trials are needed to confirm these findings and optimize treatment strategies for gastritis.
Sources and full results
Most relevant research papers on this topic
Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study
The new formulation of rebamipide 150 mg (AD-203) twice daily is not inferior to rebamipide 100 mg (MucostaR) thrice daily in treating erosive gastritis.
RCT
Large Human Trial
Rigorous JournalEfficacy and safety of Weifuchun tablet for chronic atrophic gastritis: A systematic review and meta-analysis
Weifuchun tablet is more effective than Western medicine and other Chinese patent medicine for treating chronic atrophic gastritis, but there is no significant difference in safety.
Meta-AnalysisEfficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis
Fexuprazan 20 mg q.d. and 10 mg b.i.d. for 2 weeks showed superior therapeutic efficacy and higher erosion healing rates compared to placebo in patients with acute or chronic gastritis.
RCTLarge Human TrialThe efficacy and safety of Jian-Wei-Qu-Tong Pills for the treatment of chronic non-atrophic gastritis (spleen and stomach qi deficiency with damp-heat stasis syndrome): study protocol for a phase II, randomized controlled trial
The Jian-Wei-Qu-Tong Pills (JWQTP) show potential in treating chronic non-atrophic gastritis with spleen and stomach qi deficiency and damp-heat stasis syndrome, offering an alternative treatment option for these patients.
RCT
Very Rigorous JournalEvaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Infectious Diseases Society of America and the Food and Drug Administration.
Combination regimens of bismuth salts and antimicrobial drugs show potential in relieving symptoms, eradicating H. pylori, and reducing ulcer relapse compared to other therapies.
RCTNetwork Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Atractylodes macrocephala Koidz. for the Treatment of Chronic Gastritis
Atractylodes macrocephala Koidz (AMK) may treat chronic gastritis by influencing inflammatory response, amino acid synthesis, and energy metabolism through various signaling pathways.
In Vitro StudyRole of Rebamipide and or Pantoprazole in Preventing Dexamethasone Induced Gastritis in Senile Male Albino Rats
Rebamipide has a better protective effect than Pantoprazole in preventing gastric mucosal injuries caused by Dexamethasone in senile male albino rats.
RCT
Animal StudyMitigation of Gastric Damage Using Cinnamomum cassia Extract: Network Pharmacological Analysis of Active Compounds and Protection Effects in Rats
Cinnamomum cassia extract reduces gastric damage caused by NSAIDs, ethanol, and EtOH/HCl, potentially due to its anti-inflammatory effects and suppression of inflammation-related genes and pathways.
Non-RCTAnimal StudyRigorous JournalCurrent pharmacotherapy options for gastritis
Pharmacotherapy options for gastritis include H. pylori-induced gastritis, autoimmune gastritis, and NSAID-related gastropathy, with sequential or quadruple therapy being best in regions with high clarithromycin resistance.
Literature ReviewLong-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Long-term omeprazole therapy in peptic ulcer disease leads to moderate hypergastrinemia and significant argyrophil cell hyperplasia, correlated to the severity of corpus gastritis.
Non-RCT
Highly Cited